An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS).

Trial Profile

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Expanded access
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 17 Apr 2013 Actual initiation date changed from May 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Planned snd date changed from 1 Dec 2013 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 23 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top